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ABSTRACT
Animal models are 78% accurate in determining whether drugs will alter contractility of the human heart. To evaluate
the suitability of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for predictive safety
pharmacology, we quantified changes in contractility, voltage, and/or Ca2þ handling in 2D monolayers or 3D engineered
heart tissues (EHTs). Protocols were unified via a drug training set, allowing subsequent blinded multicenter evaluation of
drugs with known positive, negative, or neutral inotropic effects. Accuracy ranged from 44% to 85% across the platform-cell
configurations, indicating the need to refine test conditions. This was achieved by adopting approaches to reduce signal-to-
noise ratio, reduce spontaneous beat rate to  1 Hz or enable chronic testing, improving accuracy to 85% for monolayers and
93% for EHTs. Contraction amplitude was a good predictor of negative inotropes across all the platform-cell configurations
and of positive inotropes in the 3D EHTs. Although contraction- and relaxation-time provided confirmatory readouts
forpositive inotropes in 3D EHTs, these parameters typically served as the primary source of predictivity in 2D. The reliance
of these “secondary” parameters to inotropy in the 2D systems was not automatically intuitive and may be a quirk of hiPSC-
CMs, hence require adaptations in interpreting the data from this model system. Of the platform-cell configurations,
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responses in EHTs aligned most closely to the free therapeutic plasma concentration. This study adds to the notion that
hiPSC-CMs could add value to drug safety evaluation.
Key words: human-induced pluripotent stem cells; cardiomyocytes; contractility; safety pharmacology; inotropy; alternatives
to animal testing; inotropy; predictive toxicology; CRACK-IT project; electrophysiology.
On average, 37 new drugs are launched to market each year but
cost of development has increased from approximately $14M
per drug in the 1960s to approximately $1.5Bn now, inflation ad-
justed (Catapult, 2018; IFPMA, 2017). Attrition rates remain high,
with only approximately 2% of the drugs entering phase 1 clini-
cal trials actually progressing to use in patients. A key concern
is cardiovascular toxicity, where acute, chronic, and comorbid-
ity effects account for 17% of the 462 drugs withdrawn from
market (Onakpoya et al., 2016) and for 41% of the top 200 pre-
scribed drugs being labeled with adverse drug reaction or black
box warnings (Fuentes et al., 2018).
Altered cardiac electrophysiology was implicated in the with-
drawal of 13 drugs from market between 1990 and 2006 (Shah,
2006). Such events led to International Conference on
Harmonization (ICH) S7B guidelines for proarrhythmic risk detec-
tion using simplified in vitro assays to measure blockade of the
rapid repolarization IKr current, commonly known as hERG (Food
and Drug Administration, 2005b). Combined with ICH E14 (Food
and Drug Administration, 2005a) guidelines on electrocardiogram
monitoring, drug withdrawal due to electrical dysfunction has re-
duced, with no reported incidences since 2007. These approaches
have improved safety, but the relatively poor specificity for pre-
dicting human outcomes and overconservativism of the assays
has raised concern that promising drug candidates may be aban-
doned too early due to false positives (Gintant, 2011).
Greater predictivity during the early stages of the drug develop-
ment pipeline will require certain attributes from the chosen
assays. These include being of human origin, suitable longevity for
acute and chronic studies, compatible with medium-throughput
analysis, reflective of working cardiomyocyte physiology and func-
tion, and compliant with 3Rs polices. This reduces the attractive-
ness or relevance of many existing systems, such as those
involving animal models. This is also true for human- and animal-
derived primary cardiomyocytes, which rapidly dedifferentiate in
culture, lose viability, or become overrun with fibroblasts.
Alternative technologies are now showing potential in car-
diovascular safety evaluation, with human-induced pluripotent
stem cell-derived cardiomyocytes (hiPSC-CMs) as a key modality
(Gintant et al., 2017). This is evidenced by their use in disease
modeling, drug discovery and cardiac safety studies, which cul-
minated in the Comprehensive in vitro Proarrhythmia Assay
(CiPA) and Japanese iPS cardiac safety assessment initiatives
(Fermini et al., 2016; Kanda et al., 2018; Sager et al., 2014). Using
CiPA as an example, the approach proposed was to identify
proarrhythmic risk based on several key modalities including:
(1) assessment of several major ion channels in transfected cell
lines; (2) in silico modeling of the ion channel effects; (3) proar-
rhythmic assessment in hiPSC-CMs; and (4) clinical assessment
of electrocardiograms from phase I human studies. Data that
emerged from CiPA show that optical- and multielectrode array-
based platforms using commercially sourced hiPSC-CMs enable
an 87% accuracy in predicting proarrhythmic liability across geo-
graphically diverse testing laboratories (Blinova et al., 2018), with
similar studies being reported by others (Bot et al., 2018).
In contrast, there have been relatively few studies that have
used hiPSC-CM contractility in predictive safety assessment
(Pointon et al., 2017). This is surprising because cardiovascular
liability of drugs occurs commonly via altered function of the
contractile myocardium. Also, monitoring contractility in
hiPSC-CMs is currently being done at low throughput or by us-
ing surrogate markers (eg, impedance) and, so far, there has
been no detailed cross-site validation study to accurately assess
the impact of drugs on hiPSC-CM contractility.
Within this context, a public-private partnership “InPulse
CRACK-IT Challenge” was established between the pharmaceutical
company, GlaxoSmithKline (GSK), and a U.K. funding agency, the
National Centre for the Replacement, Refinement & Reduction of
Animals in Research (NC3Rs). The aim was to develop medium-
throughput technology platform that could measure contractility
in hiPSC-CMs as a physiologically relevant functional output for
use in preclinical drug safety evaluation. Parallel or simultaneous
measures for Ca2þ handling and/or voltage, potentially with physi-
ological loading, were requested as part of the challenge as op-
tional parameters to multiplex mechanistically relevant endpoints
and thereby inform integrated decision making.
To this end, we established a multinational consortium,
comprising 4 academic teams in Germany, Holland, and the
United Kingdom, along with 2 biotech companies (Clyde
Biosciences; Ncardia), GSK and NC3Rs. We describe the process
by which 36 drugs were selected, distributed, and formulated,
allowing a training set of 8 drugs to be used to unify standard
operating procedures (SOPs). This enabled a multicenter study
to be undertaken for blinded evaluation of up to 28 drugs with
known positive, negative, or neutral inotropic effects, and led to
the creation of an interactive web tool to access datasets for
contractility, voltage, and/or Ca2þ handling (https://bjvanmeer.
shinyapps.io/crackit/, last accessed May 11, 2020). Overall, the
different platform-cell combinations had an accuracy of 44%–
85% in correctly predicting inotropy. With simple refinement of
the test conditions, namely by adopting approaches to reduce
signal-to-noise ratio, data variability, reduce spontaneous beat
rate to  1 Hz, and/or enable chronic testing, accuracy could be
increased to 85%–93%, comparing favorably with that currently
possible with in vivo animal models.
MATERIALS ANDMETHODS
CellOPTIQ: Adult rabbit ventricular cardiomyocytes. Rabbit hearts
were excised via a thoracotomy and submerged in a modified
Krebs-Henseleit (KH) solution of the following composition
(mmol/l): NaCl (130), KCl (4.5), HEPES (5), NaH2PO4 (0.4), MgCl2
(3.5), and Glucose (10), pH 7.25 at 37C with NaOH. Hearts were
removed and perfused retrogradely at 25 mlmin1 (37C) with a
modified KH solution containing 0.75 mmol/l [Ca2þ] for 5 min,
followed by a nominally Ca2þ-free KH solution with 0.1 mmol/
l EGTA for 5 min. Hearts were then perfused with KH solution
containing 0.24 mmol/l [Ca2þ], 1 mg/ml collagenase (type I), and
0.06 mg/ml protease (type XIV). After approximately 4–5 min,
enzyme was removed and the left ventricular free wall was
then cut into strips in the recirculated enzyme solution contain-
ing 1% bovine serum albumin before being mixed to yield a sin-
gle cell suspension. Cells were maintained in either Ca2þ-free
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KH solution or 1 mmol/l Ca2þ (via stepwise increments) until
use. Intact cardiomyocytes in 1.8 mmol/l modified Ca2þ KH solu-
tion were loaded with FluoVolt (Thermo Fisher Scientific) at
1:3000 dilution for 10 min. The incubation medium was re-
moved and the cells resuspended in a modified KH solution.
Cardiomyocytes were allowed to settle on a coverslip in a
bath (35 mm petri-dish) at 37C. Cells were field stimulated at a
frequency of 2 Hz with 2 ms duration voltage pulses delivered to
parallel graphite electrodes (stimulation voltage set to 1.5 times
the threshold) for 2 min before sampling FluoVolt and cell video
for 10 s. After repeating this for 10–12 cells/dish the drug was
added to quiescent cells and left for 30 min before returning to
the same myocytes and repeating the stimulus and data cap-
ture protocol. A parallel set of vehicle (DMSO) time control
experiments were also performed FluoVolt fluorescence
(490 nm excitation) was measured at a sampling rate of 10 KHz,
whereas the image was recorded on a CCD camera at 100 Hz
frame rate using > 700 nm light. Sarcomere length and frac-
tional shortening of sarcomere length was subsequently
extracted from the image using a FFT-based algorithm.
TTM system. The TTM system was developed and used as de-
scribed previously (van Meer et al., 2019). Briefly, the all-optical
fluorescent system consists of a microscope capable of record-
ing sequential frames while switching exposure wavelengths
within 1 ms. Using 3 LEDs at 470, 560, and 656 nm this results in
an effective recording speed of 333 Hz per parameter. Baselines
measurements (7-s recordings) were made by choosing 3 areas
per well and saving the positions to measure the same areas af-
ter drug incubation. Data were analyzed with custom software
offline and automatically to reduce used bias.
Black glass-bottom 96-well plates (Grenier) were coated with
1:100 Matrigel (Sigma-Aldrich) in DMEM F12 (Sigma-Aldrich).
Pluricyte hiPSC-CMs were thawed and plated (40 000/well in
100ml) according to manufacturer’s instructions in Pluricyte
Cardiomyocyte Medium. To help the recovery of the cells 1:100
RevitaCell (Sigma-Aldrich) was added to each well. Empty wells
around the plated CM were filled with 200ml of PBS to minimize
evaporation. Cells were refreshed with 200ml PCM medium at day
1 and day 4 or 5 after plating. All measurements for 1 drug were
always performed on days 5 and 6 or days 6 and 7 after plating.
hiPSC-CMs were labeled with ANNINE 6-plus (Sensitive
Farbstoffe GbR, Germany; stock concentration: 0.7 mM, dilution
1:833), Rhod 3 (Invitrogen; stock concentration 10 mM, dilution
1:833), and CellMask Deep Red (Thermo Fisher Scientific; stock
concentration 5 mg/ml, dilution 1:1000) in 50 ml Pluricyte me-
dium for 20 min at 37C, refreshed (200 ml Pluricyte medium),
and given 10 min to recover at 37C before recording baseline
measurements. Drug incubation took place just after baseline
measurements by removing 100 ml medium and adding 100 ml
drug solution (30 min at 37C) prepared according to formula-
tion instructions supplied by GSK.
CellOPTIQ: hiPSC-CMs. The hiPSC-CMs used were R-PAT (derived
and differentiated in house as described previously) (Mosqueira
et al., 2018; Smith et al., 2018), and iCell2 and Pluricyte (pur-
chased from Cellular Dynamics International and Ncardia).
Manufacturer instructions were followed for the commercial
hiPSC lines. For iCell2, seeding was at 25 000 cells into each well
of 96-well plates (Nunclon Delta Surface; Thermo, 167008) and
then maintained for 10 days before use in drug evaluation stud-
ies. The same plates were used for R-PAT hiPSC-CMs, which
were seeded at 40 000 cells/well and maintained until days 20
and 21 of differentiation before use. For Pluricyte hiPSC-CMs,
seeding was at 35 000 cells into each well of 96-well plates
(Greiner Bio-One; 655087) and then maintained for 8 days before
use. Confluent monolayers of R-PAT and iCell2 hiPSC-CMs were
changed into serum-free medium (SFM) (Dulbecco’s Modified
Eagle Medium [Gibco, 21969035] þ 10 mM galactose [Sigma-
Aldrich, G0750] and 1 mM sodium pyruvate [Sigma-Aldrich,
P2256] 24 h before testing). Pluricyte hiPSC-CMs were changed
into 50% SFM and 50% Pluricyte Cardiomyocyte Medium (se-
rum-free) 24 h before day of testing, and on the day of testing
were changed into SFM. For the refined conditions described for
R-PAT hiPSC-CMs, plating and maintenance were as before but
cells were received fresh RPMI-B27 medium 24 h before testing
instead of SFM.
hiPSC-CMs in 96-well plate were transiently loaded in 50 ml/
well of SFM containing FluoVolt (1:200 part B, 1:2000 part A; Life
Tech, F10488) for 20 min at 37C and 5% CO2. After incubation,
the medium was replaced with 200 ll/well of SFM. Plates were
then incubated at 37C and 5% CO2 for 15 min before recording,
which were made using a 40 (NAO.6) objective at 10 KHz. To
apply electric field stimulation, a custom-made 8 channel elec-
trode StimStrip (Clyde Biosciences Ltd) was placed in a row of a
96-well plate and connected externally to a box (DC power sup-
ply; Lavota). hiPSC-CMs were paced at a frequency of 1.2–1.7 Hz
(or 0.7–1 Hz in the refined conditions) with an amplitude of 8 V
and a pulse width of 20 ms. Recordings of 10 s were made for
each well (contractility was 100 frames/s, hence 1000 frames).
Baselines and drug addition were as described for the TTM sys-
tem. Electrophysiology data were analyzed using CellOPTIQ pro-
prietary software of Clyde Biosciences and were normalized to a
maximum amplitude of 1 and minimum of 0 to standardize
height for comparison of traces created in OriginPro (OriginLab
version 7.5). Contractility data were analyzed based on pixel dis-
placement using an ImageJ plug-in. This plug-in uses a sum of
absolute differences algorithm.
Engineered heart tissues. To generate EHTs, in-house hiPSC lines,
R-PAT, and ERC18, were differentiated using 2D-monolayer- (R-
PAT) or 3D-embryoid body- (ERC18) protocol and fabricated as
recently described (Breckwoldt et al., 2017; Mosqueira et al.,
2018). In brief, casting molds were generated in 24-well plates
with 2% agarose (Invitrogen, 15510-019) and
Polytetrafluorethylene (PTFE) spacers (EHT Technologies,
C0002). PDMS racks (EHT Technologies, C0001) were placed in
the 24-well plates so that pairs of PDMS posts reached into each
agarose casting mold. A reconstitution mix was prepared con-
sisting of: 1  106 hiPSC-CM; 81.9 ml cardiomyocyte medium;
10 ml Matrigel basement membrane matrix (BD 354234); 5.5 ml 2 
DMEM; 0.1 ml Y-27632 (10 mM; Biorbyt orb60104); 2.5 ml bovine fi-
brinogen (5 mg/ml; Sigma F4753). Reconstitution mix (97ml) was
mixed with prealiquoted 3 ml thrombin (100 U/ml; Biopur BP11-
10-1104) and pipetted into the agarose casting mold. GCAMP6f-
lentiviral particles (multiplicity of infection: 0.3, functional titer)
were included in the EHT reconstitution mix for Ca2þ transient
analysis. EHTs started to beat coherently after 10–14 days and
were analyzed for contraction and Ca2þ transient at  20 days.
EHTs were transferred from culture medium into preequili-
brated (37C, 40% O2, 7% CO2), modified Tyrode’s solution (in
mM, 120 NaCl; 22.6 NaHCO3; 5.4 KCl; 5 glucose; 1 MgCl2; 0.4
NaH2PO4; 0.6–1 CaCl2; 0.05 Na2EDTA; 25 HEPES) for R-PAT and
into DMEM (Gibco 21068028; in mM, 110 NaCl; 44 NaHCO3; 5 KCl;
25 glucose; 0.8 MgSO4; 0.9 NaH2PO4, 0.6–1 CaCl2; 25 HEPES, and
vitamins and amino acids) for ERC18 EHTs 40 min before analy-
sis to equilibrate to the testing medium. After equilibration, the
cumulative concentration response curve was started with
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baseline recording in preequilibrated medium with Ca2þ con-
centration of 0.6–1 mM.
For long-term contractility analysis of sunitinib, hiPSC-CM
EHTs were equilibrated to regular cell culture medium without
serum (DMEM, Biochrom F0415; penicillin/streptomycin 1% [vol-
ume/volume], Gibco 15140; aprotinin 5 mM, Sigma-Aldrich
A1153; insulin 1.7 mM, Sigma-Aldrich I9278; glutamine 2000 mM,
Gibco 25030-081; triiodothyronine 0.77 nM, European
Commission-Joint Research Center IRMM-469; hydrocortisone
137 mM: Sigma-Aldrich H0888). Medium change, drug addition
and video-optical contractility analysis was performed daily
and contraction data was normalized to time control.
Contractility analysis was via automated video-optical con-
tractility analysis was performed in 24-well cell culture plates
(Nunc, 122475) (Breckwoldt et al., 2017). Video files of EHT con-
tractions were analyzed by automated EHT figure recognition
software (EHT Technologies, A0001). Top and bottom ends of
EHT contour were identified and followed during the course of
recording. Force was calculated based on shortening during
contraction, elastic propensity, and geometry of PDMS posts.
Ca2þ transient analysis was combined with contraction in
24-well cell imaging plates (Eppendorf, 030741005). Briefly, set
up consisted of an inverted fluorescence microscope (Zeiss)
with a custom-made, automated, light tight, CO2- and
temperature-controlled XY-stage with 24-well plate holder. A
camera attached to front port of the microscope was used for
contraction analysis (1.25 objective) and a camera attached to
side port of the microscope was used to adjust position of the
tissue for fluorescence/Ca2þ transient measurement (10 objec-
tive). A small predefined area (0.1  0.4 mm) in the center of
EHT was used to record Ca2þ transients. Mercury lamp, GFP fil-
ter set, and photomultiplier tube were used to record change in
fluorescence in EHTs expressing GCaMP6f (increase fluores-
cence during contraction phase). Predefined XYZ coordinates
for contraction and Ca2þ transient were defined and saved in a
bespoke software which controlled microscope settings, XYZ
coordinates, and recorded automated-, sequential-contraction
and Ca2þ transients. Cumulative concentration response curves
were performed, similar to contractility analysis, for selective
concentrations based on results of contractility analysis.
Data were normalized to a pool of time-matched controls
(contractility analysis, ERC18: n¼ 22 EHTs/7.0 experiments; R-
PAT: 16 EHTs/5.0 experiments; combined contractility- and Ca2þ
transient-analysis: 21 EHTs/8.0 experiments) used for all con-
tractility/combined contractility- and Ca2þ transient-
measurements. Data are plotted as relative change to the mean
baseline, normalized to pool time control. Statistical signifi-
cance was evaluated by GraphPad Software, 1-way ANOVA with
Dunnett’s multiple comparisons test versus baseline.
Web tool. The web tool was build using the “Shiny” package in R
Language and Environment for Statistical Computing. Data
were analyzed and visualized using the packages “ggplot2,”
“reshape,” “Rfast,” “ggpubr,” “RColorBrewer,” “multcomp,” and
“tidyverse.”
RESULTS
Rationale for Selection, Handling, and Distribution of Training and
Blinded Drug Sets
Driven by the interests of the pharmaceutical industry, and spe-
cifically GSK, the 36 drugs in this study (Supplementary Table 1)
were selected on basis of: (1) commercial availability; (2)
approximate balance in numbers between positive inotropes
(PIs), negative inotropes (NIs), and no effect drugs (NE), with re-
spect to contractility; (3) inclusion of false positives or nega-
tives; (4) availability of functional data on inotropic effect on
cardiomyocyte and/or heart function from 1 or more species, in-
cluding human, spanning use in vitro, ex vivo, preclinically, and
clinically; (5) data on free therapeutic plasma concentrations
(FTPCs); (6) solubility in DMSO to allow unified testing at a maxi-
mum concentration of 0.1% v/v, which does not cause toxicity
in hiPSC-CMs; and (7) broad range of modes of action relevant to
contractility and toxicity, including modulation of ion channels
and pumps in the cell membrane (INaV1.5, IKr, IKATP, ICaL, If, NCX,
Naþ/Kþ-ATPase) or sarcoplasmic reticulum (SR) (RYR, SERCA),
b1- and b2-adrenoceptors, Ca2þ sensitivity, signaling cascades
(phosphodiesterase [PDE], adenylyl cyclase, cyclic AMP), energy
production (ATP, mitochondrial stress), myofilament response,
and myofilaments as well as less well-known mechanisms (eg,
inhibition of tyrosine kinases).
All drugs were purchased, formulated and distributed under
contractual material transfer agreement by GSK to ensure that
the same lot numbers were used by the testing laboratories.
Eight drugs were not blinded and used as a “training set” to es-
tablish the working parameters and protocols for the technol-
ogy platforms (isoprenaline, nifedipine, digoxin, BayK8644,
EMD-57033, ryanodine, thapsigargin, caffeine). The remaining
28 “test set” drugs were encoded and blinded by GSK’s Sample
Management Technology department, which dealt with han-
dling and distribution as preweighed lots in coded brown glass
vials. Samples were formulated according to prescribed, blinded
instructions, and using single-shot vials of DMSO where possi-
ble to minimize absorption of water from the atmosphere,
hence avoid inadvertent drug dilution. Powders and formulated
drugs were stored at 80C, with the solutions undergoing no
more than 2 rounds of freeze-thaw and use within 2 weeks.
Refining and Establishing Working Parameters With the Drug
“Training Set”
The training set of 8 drugs was used to unify the methods for
testing, analysis, and presentation (Supplementary Figs. 1–3).
This helped to establish SOPs (Supplementary Table 2), which
were used for subsequent blinded evaluation of the “test set”
drugs. Three technology platforms were used, differing in con-
figuration, format of wells, and approach to calculate contractil-
ity. These were the Triple Transient Measurement (TTM),
CellOPTIQ (CO), and engineered heart tissue (EHT) platforms.
The TTM platform is bespoke and was the only system in
this study that could simultaneously measure contractility,
electrophysiology, and Ca2þ handling. Interlaced 1000 frame/s
movies (ie, sequential 1 ms/channel) were recorded from hiPSC-
CMs cultured in 2D monolayers in 96-well plates loaded with
appropriate dye (Sala et al., 2018; van Meer et al., 2019). The CO is
a proprietary system that was used to measure contractility, via
bright field images, and electrophysiology, via voltage-sensitive
dyes (Duncan et al., 2017). Here, it was used on hiPSC-CMs cul-
tured in 2D monolayers in 96-well plates and isolated adult rab-
bit cardiomyocytes. Finally, the EHT system is commercially
available, using 3D constructs fabricated from hiPSC-CMs using
a fibrin hydrogel between 2 polydimethylsiloxane (PDMS) posts
and multiplexed in 24-well plates (Mannhardt et al., 2016).
Determining Ca2þ handling required viral transgenesis of a ge-
netically encoded calcium indicator (GCAMP6f) during EHT fab-
rication. Whereas pixel displacement was used as a surrogate of
contractility in the 2D systems (TTM and CO), 3D EHTs enable
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force of contraction to be calculated from the extent of deflec-
tion of PDMS posts upon each beat.
Action potential duration (APD30, APD90) and triangulation
(APD90–APD30) were calculated from voltage waveforms to de-
termine whether electrophysiology was altered, including the
appearance of arrhythmias. For Ca2þ handling, amplitude, time
to peak, and decay time were assessed, whereas similar param-
eters (contraction amplitude [CA], contraction time [CT], and re-
laxation time [RT]) were derived for contraction (Supplementary
Figure 2). Contractility responses were further subdivided
(Supplementary Figure 2), such that positive inotropy reflected
an increase in CA, positive clinotropy a decrease in CT and posi-
tive lusitropy a decrease in RT. The opposite is true for negative
responses.
The training set of 8 drugs was used to test and refine proto-
cols. Representative data are shown for the PIs, digoxin/isopren-
aline, and the NI, nifedipine (Supplementary Figure 3). For each
parameter, the percentage change in drug-treated samples rela-
tive to their respective vehicle control was calculated using the
formula ([drug/drug baseline]/[vehicle/vehicle baseline])*100–
100. Consistent with the mode of action of these drugs, in all
cases there was a trend or significant response for positive ino-
tropy (increased CA) in hiPSC-CMs treated with digoxin/isopren-
aline but negative inotropy (decreased CA) for those treated
with nifedipine (Supplementary Figure 3). Digoxin tended to in-
crease RT in 2D configuration, whereas isoprenaline decreased
of both CT and RT in 3D EHTs (Supplementary Figure 3). These
studies allowed unification of SOPs, although physical and tech-
nical constraints between the platforms meant that some un-
avoidable differences remained (Supplementary Table 2).
Blinded Evaluation and Assignment of Drug “Test Set”
Using the SOPs established above, up to 28 blinded drugs were
tested in a rank order that was predefined by GSK (Table 1).
Contraction was the parameter common to all platforms be-
cause the primary aim of the study was to predict whether
drugs were positive, negative, or neutral inotropes.
Differentiation of the in-house hiPSC lines, R-PAT, and ERC18,
provided sufficient hiPSC-CMs to test all available drugs on the
CO and/or EHT platforms. Testing was restricted to 10 drugs in
rabbit CMs (as a comparator) and in commercial hiPSC-CMs
(Pluricyte and iCell2) due to cost, availability and timelines,
whereas throughput was a limitation of the TTM system.
Overall, 9 drugs were tested in common across all platform-cell
combinations, which were later unblinded and identified as:
PIs, epinephrine, forskolin, levosimendan, pimobendan; NIs, ve-
rapamil, sunitinib; NE, acetylsalicylic acid, atenolol, captopril.
All data for contraction, voltage, and Ca2þ handling across
the various platform-cell combinations are accessible via an in-
teractive web tool via https://bjvanmeer.shinyapps.io/crackit/.
Representative data for contractility illustrates the output for-
mat for 6 drugs where the response was generally predicted cor-
rectly or incorrectly, respectively. Thus, data are shown for the
PIs, epinephrine, and levosimendan (Figure 1A), NIs, verapamil,
and sunitinib (Figure 1B), and NE drugs, acetylsalicylic acid, and
captopril (Figure 1C). In some instances, data from Ca2þ and, to
a lesser extent, voltage analyses were used to assist in predic-
tion of inotropic response, as was the case for the PI, epineph-
rine, and the NI, verapamil (Supplementary Figs. 4A and 4B).
Prediction of inotropy involved a 2-day face-to-face meeting
between all investigators, with colleagues from GSK overseeing
the process as observers rather than contributors. Each
platform-cell-drug combination was evaluated individually and
a consensus between the research team on the outcome was
established using the terminology defined in Supplementary
Figure 2 (ie, positive or negative inotropy [CA], clinotropy [CT],
and lusitropy [RT]; altered electrophysiology 6 arrhythmias [AE
6 *]; altered Ca2þ). In some cases, decisions were based on
trends rather than statistical significance. For example, this was
true for TTM: Pluricyte evaluation of epinephrine (Figure 1A, see
CA and CT). Once predictions were finalized, the document was
“locked” and drugs were unblinded by GSK to allow comparison
with their known effects (Tables 1 and 2).
Across the 9 drugs evaluated in common, all platforms
mainly predicted NE drugs and NIs (Table 2). One exception was
sunitinib, which was poorly detected by the EHT platform. This
may be due to slower penetration, lower sensitivity, and greater
cell community effect of 3D tissues protecting against short-
term (30 min) exposure to this chronic toxicant. Poorest predic-
tivity was for PIs, which ranged from 0% to 50% accuracy.
Overall predictivity for the 9 drugs ranged from 44% to 78%. This
range was similar across all drugs tested (50%–85%), with NE
and NI being predicted most accurately (up to 100%; Table 2).
The trend was for the EHT:hiPSC-CM combination to be more
predictive of PIs (75%) than CO: hiPSC-CM (0%–25%). Together,
these data implied that continuous measurements from 3D
preparations of hiPSC-CMs yielded more predictive contractility
data than cell motion sampled from a 2D culture.
We looked for trends in the data that might point toward
ways to improve the process of predicting response. The drug
concentration at which the maximum responses were recorded
were broadly similar across the TTM, CO, and EHT platforms, ir-
respective of whether prediction was correct (Table 1). However,
we noted that the response range was wider in 2D relative to 3D
platforms. Whereas mean maximum measurable percentage
changes in CA for the TTM and CO platforms ranged from
100% to þ196%, it was 100 to þ53% for the EHT platform
(Table 1). Where there was an increase in CA, the standard devi-
ation of these mean values was 41.5 versus 12.1 for the 2D ver-
sus 3D platforms. A similar pattern was observed for NIs, and
for changes in CT and RT. This was corroborated by the wider
distribution of data points in the 2D platforms relative to the 3D
platform (Figs. 1A–C, Supplementary Figs. 4A and 4B, web tool).
This likely relates in part to the cumulative concentration re-
sponse protocol used for EHTs (Supplementary Table 2).
These observations prompted us to examine sensitivity of
the different platforms. Where platform-cell combinations cor-
rectly predicted inotropy, data were converted into a heat map
to reflect the percentage change for PIs (Figure 2A) and NIs
(Figure 2B). In 6/7 correctly predicted cardio-active PIs, 1 or more
contractile parameters (CA, CT, and/or RT) recorded from EHTs
reached statistical significance at concentrations within, or
close to, the FTPC range, whereas 2D platforms appeared to be
less sensitive (Figure 2A). This is illustrated by epinephrine,
where significant changes (p of  .05, Dunnett’s post-test) in CT
and RT were detected within the FTPC range at a sensitivity of
10- to 100-fold greater than the 2D platforms, and a similar pat-
tern was seen for forskolin (Figure 2A). These trends did not ex-
tend to NIs, presumably because on- or off-target cardiac
toxicity associated with a proportion of compounds in this
group will be occurring after longer incubation times and at
higher concentrations than those used for therapeutic benefit,
which is reflected in the FTPC.
Finally, we investigated which parameter was most informa-
tive (Figure 3). Where prediction was correct, we asked which
parameter within these in vitro models reached significance at
the lowest drug concentration. Pooled data from both PIs and
NIs showed no clear distinction between CA, CT, and RT.
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Figure 1. A, Contraction analysis across the platform-cell combinations for PIs. Examples are given to illustrate when some or all platform-cell combinations enable
correct or incorrect predictions of the PIs, epinephrine, and levosimendan, respectively. The table indicates where decision making was guided by data from Ca2þ tran-
sients and/or voltage, with example data provided for epinephrine and verapamil in Supplementary Figures 4A and 4B. Red dotted line is free therapeutic plasma con-
centration (FTPC). Dunnett’s stats versus vehicle control: *p< .05; **p< .01; ***p< .001; ****p< .0001. B, Contraction analysis across the platform-cell combinations for NIs.
Examples are given to illustrate when some or all platform-cell combinations enable correct or incorrect predictions of the NIs, verapamil, and sunitinib, respectively.
The table indicates where decision making was guided by data from Ca2þ transients and/or voltage, with example data provided for epinephrine and verapamil in
Supplementary Figures 4A and 4B. Red dotted line is FTPC. Dunnett’s versus vehicle control: *p< .05; **p< .01; ***p< .001; ****p< .0001. C, Contraction analysis across the
platform-cell combinations for NEs. Examples are given to illustrate when some or all platform-cell combinations enable correct or incorrect predictions of the NEs,
acetylsalicylic acid, and captopril, respectively. Red dotted line is FTPC. Dunnett’s stats versus vehicle control: *p< .05; **p< .01; ***p< .001; ****p< .0001. Abbreviations:
CO, CellOPTIQ; EHT, engineered heart tissue; TTM, Triple Transient Measurement.
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Figure 1 B, Continued
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Figure 1 C, Continued
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Table 2. Predictivity Tables and Scores
Platform:Cell Combination Config. Nine Drugs in Common All Drugs Assessed
PI (%) NI (%) NE (%) Total (%) PI (%) NI (%) NE (%) Total (%)
CellOPTIQ Rabbit CMs 2D 2/4 (50) 2/2 (100) 2/3 (67) 6/9 (67) 2/4 (50) 2/2 (100) 3/4 (75) 7/10 (70) Color key of
predictivity
scores
TTM Pluricyte hiPSC-CMs 2/4 (50) 2/2 (100) 3/3 (100) 7/9 (78) 2/4 (50) 2/3 (67) 3/3 (100) 7/10 (70) Predictivity of
> 75%CellOPTIQ Pluricyte hiPSC-CMs 0/4 (0) 2/2 (100) 3/3 (100) 5/9 (56) 0/4 (0) 2/3 (67) 3/3 (100) 5/10 (50)
iCell2 hiPSC-CMs 1/4 (25) 2/2 (100) 3/3 (100) 6/9 (67) 1/4 (25) 2/3 (67) 3/3 (100) 6/10 (60) Predictivity of
50%–74%R-PAT hiPSC-CMs 0/4 (0) 1/2 (50) 3/3 (100) 4/9 (44) 0/8 (0) 5/9 (56) 10/10 (100) 15/27 (56)
EHT R-PAT hiPSC-CMs 3D 2/4 (50) 1/2 (50) 3/3 (100) 6/9 (67) 6/8 (75) 8/9 (89) 9/10 (90) 23/27 (85) Predictivity of
< 50%ERC hiPSC-CMs 2/4 (50) 1/2 (50) 3/3 (100) 6/9 (67) 6/8 (75) 8/9 (89) 8/10 (80) 22/27 (81)
Collective data are presented for cross comparison between platform-cell combinations relating to the 9 drugs tested in common or all drugs evaluated. Green shading
shows predictivity of > 75%, orange of 50%–74%, and red of < 50%. Predictivity is gauged as whether the assignment made by the investigators matched the assignment
made by the commercial sponsor, GlaxoSmithKline, and the available literature described in Supplementary Table 1.
Figure 2. A, Sensitivity of platform-cell combinations for predicting positive inotrope (PIs). Where PIs were correctly predicted, data are presented as percent change
relative to baseline for any of the 3 contractility parameters (CA, contraction amplitude; CT, contraction time; RT, relaxation time). The bolded black text indicates
where significance was reached using Dunnett’s stats versus vehicle control and p< .05. B, Sensitivity of platforms-cell combinations for predicting negative inotropes
(NIs). Where NIs were correctly predicted, data are presented as percent change relative to baseline for any of the 3 contractility parameters (CA, contraction amplitude;
CT, contraction time; RT, relaxation time). The bolded black text indicates where significance was reached using Dunnett’s stats versus vehicle control and p< .05.
Abbreviations: CO, CellOPTIQ; EHT, engineered heart tissue; FPTC, free plasma therapeutic concentration; NR, not recorded; TTM, Triple Transient Measurement.
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Figure 2. B, Continued
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However, segregation showed that CA was clearly most infor-
mative parameter for NIs. In contrast, CT was highly informa-
tive for PIs and particularly those with cAMP-mediated modes
of action, with some contribution being derived from RT in
hiPSC-CMs and CA in rabbit CMs.
Understanding Why Incorrect Assignments Were Made and
Improving Test Platforms
The data above highlighted several deficiencies, including: (1)
the discrimination of changes in contractility assessed from in-
termittent video measurements using a motion algorithm on
2D systems was lower than the continuous tension measure-
ments on 3D systems, (2) detection of PIs was challenging, par-
ticularly to 2D platforms, and (3) chronic toxicants, such as
doxorubicin, were poorly predicted after the acute (30 min)
treatment duration.
We reasoned that medium composition may be a contribut-
ing factor in signal-to-noise ratio and poor detection of PIs. This
was because, on the CO platform, switching from protein-
containing (RPMI-B27) to serum-/protein-free medium in-
creased the mean beat rate from 0.7 to  1.2 Hz (Supplementary
Figure 5; p .0001, Mann-Whitney). This was concurrent with
increased spread of the data for CA, CT, and RT, wherein the
standard deviations for RPMI-B27 versus serum-/protein-free
medium were 12.1 versus 32.8, 14.5 versus 20.1, and 10.7 versus
26.9, respectively (Supplementary Figure 5). It has previously
been reported in native heart muscle preparations that lower
beating rate is associated with a positive force-frequency rela-
tionship (up to approximately 2 Hz) and stronger inotropic
effects of most PIs (Butler et al., 2015). Therefore, we retested PIs
from the test set of drugs using CO:R-PAT, because this plat-
form:cell combination proved poorly predictive (0/8) in the
blinded study. In these revised testing conditions, 6/8 PIs
showed reduced CT and/or RT (Figure 4).
We extended these studies to the 3D EHT platform, this time
slowing spontaneous beating to < 0.5 Hz with 300 nM ivabra-
dine, a pharmacological blocker of the “funny” If current (Bois
et al., 1996). Notably, these “slowed” EHTs could faithfully follow
electrical pacing in increments from 0.5 to 2.5 Hz
(Supplementary Figure 6). Whereas force-frequency relation-
ships was negative above 1.5 Hz, it was positive between 0.5 and
1.5 Hz, evidenced by a 147% increase in force generation concur-
rent with significant shortening of CT and RT (Supplementary
Figure 6). We therefore re-evaluated 6 of the PIs in the presence
of 300 nM ivabradine with electrical pacing at 0.5, 0.7, 1.0, 1.5,
and 2.0 Hz. These also included epinephrine, levosimendan,
and pimobendan, which had been incorrectly predicted by
EHT:R-PAT and/or EHT:ERC platform-cell combinations.
Notably, for all 6 drugs, positive inotropy was evident via
increases in CA but only at 0.5 and 0.7 Hz, and sometimes at
1 Hz, but never at 1.5 or 2 Hz (Figure 5). Consistent with this,
shortening of CT was observed for all drugs acting via increased
cAMP, with the largest changes often occurring at the lower pac-
ing frequencies (Figure 5). Thus, in both 2D and 3D configura-
tions, lower beating frequencies led to increased predictivity for
PIs.
Finally, we considered NIs that had been incorrectly pre-
dicted (or not tested), including doxorubicin and sunitinib.
Although 30 min exposure of hiPSC-CMs to these anticancer
drugs altered electrophysiology, effects on contractility were
predicted with variable accuracy (Table 1, web tool). We asked
whether longer term exposure would affect contractility
(Supplementary Figure 7). The CO:R-PAT platform-cell combina-
tion showed that exposure to the highest concentration of ei-
ther drug for 24 h led to loss of contraction and cell death.
Similarly, using the EHT:ERC platform-cell combination, expo-
sure to doxorubicin ceased EHT contraction after 17.5 h,
whereas exposure to 1 mM sunitinib led to a decline in CA over a
7-day period (Supplementary Figure 7). Thus, although short-
term exposure to these NIs perturbed the electrophysiology of
hiPSC-CMs, longer term exposure caused overt cytotoxicity and/
or negative inotropy.
DISCUSSION
Through blinded testing across multiple geographical sites, we
evaluated the ability of 7 different platform-cell combinations
to predict whether drugs of interest to the pharmaceutical
Figure 3. Most informative contractility marker. Parameters that led to the cor-
rect prediction of drug responses were assessed. Data show the breakdown by
percentage for the parameters (CA, contraction amplitude; CT, contraction time;
RT, relaxation time) that reached significance at the lowest concentration
(Dunnett’s stats vs vehicle control and p< .05). White boxes (NS, not significant)
indicate where predictions were made due to a trend rather than reaching sig-
nificance, and/or by guidance from Ca2þ and/or voltage data. Abbreviations: CO,
CellOPTIQ; EHT, engineered heart tissue; TTM, Triple Transient Measurement.
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industry were positive, negative, or neutral inotropes. We
achieved this by examining contractility parameters (CA, CT,
and RT), as well as using Ca2þ transients and/or electrophysiol-
ogy to assist in decision making in some instances. Within the
context of these in vitro models, we found that CA was the most
informative parameter for NIs. Particularly after refinement in-
volving slowing of beat rate to below 1 Hz (Figure 5,
Supplementary Figure 6), CA was highly informative of PIs in
the EHT system but far less so in the 2D systems. Although con-
traction- and relaxation-time provided confirmatory readouts
for PIs in 3D EHTs, these parameters typically served as the pri-
mary source of predictivity in 2D (Figure 4), especially where the
mode of action involved cAMP signaling.
We propose that an efficient way to predict the inotropic ef-
fect of drugs would be first to conduct acute (30 min) testing in
hiPSC-CMs. Spontaneous beat rates should be < 1 Hz, which can
be achieved by modifying the culture medium, using pharmaco-
logical blockage with ivabradine, and/or selecting hiPSC-CMs
with slow intrinsic rates. In EHTs, this approach unveiled a clear
positive force-frequency relationship. If no changes in inotropy
are detected in the acute assay, then exposure times can be in-
creased to  24 h to determine whether the drugs have a chronic
effect. These timelines were suggested by GSK (ie,  30 min con-
sidered as acute;  24 h as chronic), which proved to be a useful
approach because it allowed a predictive accuracy of 85% in 2D
monolayers and 93% in 3D EHTs.
In reaching these refined conditions, we noted greater im-
portance of the cell preparation protocol, testing conditions,
methods of measuring contractility, and 2D versus 3D than the
cell type used, which was not necessarily expected. There were
differences in the purity/composition of the different cell types
and in their baseline electrophysiological characteristics, which
partly reflects their maturity state at single cell level
(Supplementary Table 3). However, there was not an obvious
correlation between these differences and predictivity. For ex-
ample, initial testing of the same cell type (Pluricyte hiPSC-CMs)
on 2 platforms (TTM and CO) gave different accuracies (78% vs
56%). The same was true for R-PAT hiPSC-CMs on the EHT and
CO platforms (67% vs 44%).
Modifying both the culture environment (by including a pro-
tein source that caused a beat rate to be slowed, and signal-to-
noise ratio and data variability to be reduced) and the drug ex-
posure conditions (by including both acute chronic testing for 
min and  24 h, respectively) for the CO:R-PAT combination
allowed the accuracy of prediction using this cell line to be in-
creased to 85%. It is possible that further improvements could
be made, whilst simultaneously shedding light on mechanism
of action. For example, analysis of data during different stages
Figure 4. Refined culture conditions increase predictivity of positive inotropes (PIs) in 2D monolayers of hiPSC-CMs. Contraction analysis was carried out on the 8 PIs
from the drug test set using the CO:R-PAT platform-cell combination. Only CT and RT are shown because data in Figure 3 showed these to be the most informative
parameters for PIs. Whereas testing in serum-/protein-free medium failed to identify any PIs correctly (A, web tool), the slowed beat rate and improved signal-to-noise
ratio afforded by culture in RPMI-B27 allowed correct identification of 6/8 PIs by significant decreases in CT and/or RT. Red dotted line is free therapeutic plasma con-
centration. Dunnett’s stats versus vehicle control: *p< .05; **p< .01; ***p< .001; ****p< .0001.
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of relaxation identified positive lusitropy for dobutamine (at
50% relaxation) and late relaxation deficit for ivabradine (at 80%
relaxation). During the blinded phase, we also correctly pre-
dicted that drug rank 14 was omecamtiv mecarbil on account of
the unusual response of increased CT (approximately þ40%)
without convincing evidence for increased CA (Malik et al.,
2011). This shows the value of applying pharmacological knowl-
edge to drug responses in hiPSC-CMs to derive mechanistic in-
formation out of multiparametric assessments, in this case
combined evaluation of CA, CT, and RT in hiPSC-CMs configured
as 3D EHTs, in this case combined evaluation of CA, CT, and RT
in hiPSC-CMs configured as 3D EHTs.
Another consideration is the difference between single cells,
continuous monolayers, and 3D engineered constructs. The sin-
gle rabbit cardiomyocyte assay used near-physiological rates of
stimulation (2 Hz) and subphysiological rates (1 Hz or lower)
may have improved scope to detect PIs. In adult heart prepara-
tions, a common feature of PI interventions that raise
intracellular Ca2þ is the occurrence of spontaneous diastolic SR
Ca2þ release. This phenomenon is linked to negative inotropy
and arrhythmic behavior in single cells and intact myocardium
(Allen et al., 1985; Hess and Wier, 1984). In this study, spontane-
ous diastolic Ca2þ release and associated diastolic shortening
was observed in isolated rabbit myocytes in response to b-adre-
noreceptor stimulation and drugs that raise cAMP directly (eg,
forskolin), but this phenomenon was not reported in any of the
hiPSC-CMs platforms. This is consistent with the minimal in-
volvement of the SR in excitation-contraction coupling typically
seen in embryonic cardiomyocytes and hiPSC-CMs (Knollmann,
2013); in this context, the PI effect from cAMP arises mainly
from cAMP-mediated stimulation of L-type Ca2þ current.
Out of necessity, preparations of native adult CMs are dis-
persed and seeded as cultures of single cells. It is known that
variance in cell density influences electrophysiological parame-
ters (Du et al., 2015), particularly within, and between, prepara-
tions of single cell preparations, including hiPSC-CMs
Figure 5. Slowed beat rate increases the predictivity of positive inotropes (PIs) in 3D engineered heart tissues (EHTs). Contraction analysis was carried out using EHTs
with 6 of the PIs from the drug test set: epinephrine (Epi), forskolin (For), levosimendan (Lev), pimobendan (Pim), dobutamine (Dob), and milrinone (Mil) which had
been predicted with variable accuracy (Figure 4A, web tool). In all cases, the drugs (applied as a high concentration bolus) increased contraction amplitude (CA) but
only at 0.5 and 0.7 Hz, and sometimes at 1 Hz, with the largest effects seen in contraction time (CT) also often occurring at these frequencies. Scatter plots show per-
centage changes relative to baseline at respective frequency. Averaged peaks for force are shown for baseline (BL, black peaks) versus after treatment in EHTs paced at
0.5 Hz (blue peaks) or 2.0 Hz (red peaks). Dunnett’s stats versus baseline at respective frequency: *p< .05; **p< .01; ***p< .001; ****p< .0001.
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(Mosqueira et al., 2018). Therefore, although the structural and
function (eg, prevalent SR) maturity of adult native adult CMs
from rabbit is an advantage over hiPSC-CMs, this is offset by the
high level of heterogeneity of single cell preparations, which
reduces the discrimination power. Although some of the differ-
ences will be due to the physiology of rabbit CMs relative to hu-
man CMs, we have also seen higher variability in human atrial
trabeculae as compared with hiPSC-EHT; hence, there are sepa-
rate challenges in using native cells. It is for these reasons we
elected to use hiPSC-CMs within 2D or 3D syncytium, where in-
dividual cell-to-cell variability is averaged due to mechanical
and electrical coupling. In addition, several studies have shown
previously that the EHT format compared with standard 2D cul-
ture favors maturation in terms of MDP and upstroke velocity
(Lemoine et al., 2017, 2018), structure (Mannhardt et al., 2016),
and metabolic preference (Ulmer et al., 2018).
Blinded analysis was done using serum-/protein-free me-
dium, with the intention of avoiding protein-drug binding that
might blunt the responses within the in vitro system. However,
at least in the CO:R-PAT platform-cell combination, serum-/pro-
tein-free medium was a hindrance, leading to high spontaneous
beat rates, and poor signal-to-noise ratio ratios. These issues
were abrogated by using protein-containing medium (RPMI-
B27), which enhanced the accuracy of predicting PIs on the
CO:R-PAT platform from 0% to 75%. This indicates that, for this
purpose, the benefits brought by the protein-containing
medium outweigh the concerns of drug binding and batch-to-
batch variations of protein ingredients. Nevertheless, voltage-
sensitive dyes, such as FluoVolt, interact with proteins and
reduce the signal-to-noise ratio, which make simultaneous re-
cording of contraction and voltage challenging, although this
may be overcome by measuring extracellular voltage.
Treatment of hiPSC-CMs with doxorubicin for 30 min caused
changes in electrophysiology (eg, triangulation, see web tool)
and hence gave a distinctive response compared with NEs such
as acetylsalicylic acid. Nevertheless, this acute exposure did not
always cause changes in inotropy, which shows the importance
of examining an appropriate concentration range and/or expo-
sure times of drugs. Increasing exposure time to approximately
1–7 days unveiled doxorubicin and sunitinib as NIs, consistent
with the extended timescale over which cardiac toxicity
presents clinically and is in line with data from a previous study
using TKI-inhibitors (Jacob et al., 2016). Interestingly, with 24 h
of doxorubicin treatment, the CO:R-PAT platform-cell combina-
tion appeared to show a trend of positive inotropy from 1 to
30 mM (increased CA; decreased CT) but cell death at 10 mM. This
aligns with reports indicating the effects of doxorubicin are
complex in that transient positive inotropy is followed by robust
negative inotropy at higher concentrations (Kim et al., 1980;
Vanboxtel et al., 1978; Wang and Korth, 1995).
The levels of accuracy of up to 93% in predicting drug-
induced changes in contractility in human hearts under these
refined conditions are favorable relative to those from animal
models (Lawrence et al., 2008; Valentin et al., 2009). They are also
comparable with data using 3D cardiac microtissues containing
hiPSC-CMs, cardiac endothelial cells, and cardiac fibroblasts,
which correctly predicted 23 of 29 (85%) inotropes across a non-
blinded panel of compounds (Pointon et al., 2017). These find-
ings are encouraging, but it is not always straightforward to
translate hiPSC-CM-related parameters of CA, CT, RT, and chro-
notropy (beat rate) to clinically relevant data. We have sug-
gested that data derived from hiPSC-CMs on CA is informative
for NIs in all cell-platforms combinations and for PIs in the 3D
EHT platform. However, in the 2D systems, CT, and RT may be
informative for PIs. We have considered different explanations
for this observation. If 2D systems are less adept at showing an
increase in CA, then decreases in CT (clinotropy; also expressed
as an increase in dF/dt) or decreases in RT (lusitropy; also
expressed as an increase in dF/dt) become more important. By
considering pF/dt values, which can change independently of
the peak force, there is alignment with the effects seen in vivo,
which are often expressed as a change in dP/dtmax or dP/dtmin.
An alternative explanation is that, although this is not automat-
ically intuitive, it may be a quirk of hiPSC-CMs; as a model sys-
tem, there are limitations and adaptations in thinking need to
be made. Nevertheless, the robustness of this notion will need
to be tested on a wider range of drugs to determine whether
these in vitro parameters are relevant to in vivo cardiac
physiology.
Effects on cardiac contractility per se may not indicate or pre-
dict a clinically relevant detrimental effect on the heart. For ex-
ample, cardio-active L-type calcium channel blockers are used
for treatment of hypertension. Additional “structural” end-
points, such as mitochondrial membrane permeability (Dwm),
endoplasmic reticulum integrity, contractile filament expres-
sion/organization, ATP depletion, and cardiac troponin levels in
hiPSC-CM-based assay platforms may add interpretive value to
functional changes (Sala et al., 2018). A limitation of our study
was that some modes of action were not represented in the
drug panel, such as the SERCA activator CDN1163 (Dahl, 2017;
Kang et al., 2016), or the myosin inhibitor blebbistatin (Kovacs
et al., 2004), and these would be interesting to include in blinded
assays in the future.
In our study, we looked for trends or significant changes in
the parameters measured, but did not apply a cut off on how
much change was considered meaningful (eg, > 15% change and
statistical significance). Whether analysis can be modified in
the future is for consideration but would need to be done with
care. The NE drugs, enalaprilat, tolbutamide, and pravastatin
caused changes of 19%–33% in CA on the EHT platform and
were incorrectly predicted as PIs. However, these magnitudes of
changes were similar or greater than those recorded for PIs, and
so adding thresholds on CA would not have improved predic-
tion and could have been detrimental. Relationship to FTPC was
not a strong association either, with the maximum changes of
the incorrectly predicted NEs varying from 3-fold below the
FTPC (tolbutamide) to > 100-fold above (enalaprilat, prava-
statin). This also underscores the importance of technical preci-
sion and inclusion of time controls in each single experiment,
particularly in strategies employing cumulative concentration-
response analyses which take time.
These observations likely reflect the complexity of drug-cell
interactions, which means differential effects can occur depen-
dent on the concentration and categorizing as PI, NI, and NE
was difficult in some cases. Inotropic effects of high concentra-
tions of sulphonylureas, such as tolbutamide, have been
reported for in vitro systems (Huupponen, 1987). Angiotensin
converting enzyme (ACE) inhibitors, such as enalaprilat, lead to
bradykinin accumulation and thereby lead to bradykinin B1 re-
ceptor activation, which elevates intracellular Ca2þ and causes
a positive inotropic effect (Ignjatovic et al., 2002). Similarly,
phentolamine is a neutral inotrope at free plasma concentra-
tions of approximately 2.5 mM in patients (Wallis et al., 2015), but
at concentrations above 10 mM phentolamine causes negative
inotropy via modulation of fast sodium and L-type calcium
channels (Rosen et al., 1971; Sada, 1978). This is consistent with
our data, indicating that there are multiple pharmacological
effects of this compound. For ivabradine the concentrations
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provided were much higher than the FTPC, which can lead to
off-target effects of poorly selective drugs (Choi et al., 2016). In
some cases, such as zimelidine, the difficulty arose due to lack
of robust in vitro data within the literature (Forsberg and
Lindbom, 2009; Lindbom and Forsberg, 1981; Naranjo et al.,
1984). Care must therefore be used when (1) selecting test com-
pounds by primary pharmacology and (2) using in vitro assay
paradigms to predict in vivo, clinically relevant cardiotoxicity, ei-
ther when used as a “screening assay” to rank compounds or as
a reflex investigative assay eg, following detection of cardiotox-
icity in animal toxicology studies.
Because PIs are cardio-active drugs, it might be expected
that the FTPC aligns with responses from hiPSC-CMs. This was
true for the EHT platform, where significant responses were
within, or close to, the FTPC. However, both the pharmacologic
or statistical sensitivity of 2D hiPSC-CM cultures and isolated
single rabbit cardiomyocytes were considerably lower. Two
explanations may account for these observations. First, the
greater stability of CMs in 3D constructs permitted cumulative
dosing of EHTs within the same well, which created tighter
datasets than the 2D systems, where parallel dosing in separate
well was required. Second, in contrast to 2D monolayers that
evaluated hiPSC-CM movement in unloaded conditions, the
EHT platform measures force of contraction under loaded con-
ditions (Eder et al., 2016). This facilitates maturation and Frank-
Starling mechanisms for force generation are followed, leading
to higher basal tone and cAMP signaling (Huupponen, 1987;
Uzun et al., 2016), which are important modes of action of the
PIs epinephrine, forskolin, and milrinone. Consistent with this,
positive inotropy of milrinone was shown in “Biowire II” tissue
engineered constructs, which also places hiPSC-CMs under
loaded conditions to facilitate maturation (Zhao et al., 2019).
To measure whole heart function and its integration with
neurohormonal or hemodynamic feedback, numerous assess-
ment parameters are used, including Pmax, dP/dtmax (max rate of
change if pressure) and left ventricular ejection fraction (Guth
et al., 2015). Atenolol, a selective b1-adrenoceptor antagonist,
requires intact sympathetic innervation and is an NI in the
clinic but shows NE in hiPSC-CMs (Kaumann and Blinks, 1980;
Lemoine et al., 1988). Similarly, the mode of action for clonidine
is through presynaptic alpha-adrenoceptors on sympathetic
neurons with the consequence of reduced sympathetic drive
and its effect on heart function (reduced heart rate and force)
(Jarrott et al., 1979; Kleiber et al., 2017), but these effects would
not be detected in a “cardiomyocyte only” model. Predictive
screening will also benefit from inclusion of auxiliary cell types,
such as neural lineages to enable evaluation of drugs that work
via the neurohormonal system.
Other issues that need to be considered for the future in-
clude throughput, user variability, cell availability, cost, and
batch-to-batch variability. Although the TTM platform allowed
simultaneous measurement of contraction, Ca2þ handling, and
voltage, the low throughput meant that only 10 drugs were eval-
uated in 1 hiPSC-CM line. User variability has been noted in
other studies. For example, variations in TdP predictability
across different sites using identical instruments were reported
in the CiPA study13, and so could be a factor in the site to site
differences we observed. Cost was another factor, wherein each
drug assessed typically required 1.6 million (40 wells in a 96-
well plate) and 5 million (5 EHTs) hiPSC-CMs, corresponding to
up to approximately $3000 per drug at current prices. For these
reasons, most of the assays in this report were done using
hiPSC-CMs produced “in house,” where cost for 1.6 or 5 million
cells is approximately $16 or $50, respectively, albeit without
the same level of quality control of commercial cells.
Nevertheless, for both in house and commercial cells, batch-to-
batch variation meant that the drug assays need to be repeated.
These issues become more prominent when larger tissue engi-
neered constructs are used. For example, “heart-in-a-jar” tech-
nologies, produce miniature 3D engineered electro-
mechanically coupled cardiac organoid chamber that mimic
pumping action similar to natural heart but require 10 million
hiPSC-CMs (Li et al., 2018). Thus, it is encouraging that scaled
production of hiPSC-CMs is now becoming relatively routine
and so costs should decrease in the near future.
Altogether, this study suggests that, even in their current
status of technology evolution, hiPSC-CMs cultured in 2D and
3D may have value to predictive safety pharmacology. Given
the high resource and costs involved with drug development,
even modest improvements in the pipeline could have large so-
cioeconomic and 3R benefits. More than 6000 putative medi-
cines are in preclinical development, using millions of animals
at an annual total cost of $11.3Bn, and so each percentile reduc-
tion equates to approximately $100 M. Similarly, reducing drug
attrition in phase 1 clinical trials by 5% could reduce develop-
ment costs by 5.5%–7.1%. Building on our work with further im-
provement and validation studies, conducted in a blinded
manner, will facilitate uptake of hiPSC-CMs as a routine tool in
safety pharmacology.
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